Joined Nov 11, 2007
31,929 Blog Posts

$MRK Posts Better Than Expected Results

Merck KGaA (MRK), the German maker of the cancer drug Erbitux, reported third-quarter profit that exceeded analyst estimates and increased the full-year sales forecast on higher demand for its medicines.

Earnings before interest, taxes, depreciation and amortization excluding one-time items climbed 16 percent to 754.2 million euros ($960.8 million) from 652.5 million euros a year earlier, said in a statement. Analysts had predicted 739.9 million euros, the average of estimates compiled by Bloomberg.

Merck, which isn’t related to U.S. drugmaker Merck & Co., is eliminating jobs, closing facilities and reviewing its pipeline amid setbacks for some key medicines and declining sales of Erbitux. The German company has a target to save 300 million euros by 2014 as it expands outsideEurope, particularly in the U.S., Japan and China.”

Full report

If you enjoy the content at iBankCoin, please follow us on Twitter